| Gene symbol | WT1 | Synonyms | AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1, WT33 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | WT1 transcription factor | ||||
| GTO ID | GTC1552 |
| Trial ID | NCT02550535 |
| Disease | Acute Myeloid Leukemia | Myelodysplastic Syndrome |
| Altered gene | WT1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | WT1 TCR-T cells |
| HLA | HLA-A*02:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | Single Arm Phase I/II Study of the Safety and Efficacy of Gene-modified WT1 TCR Therapy in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) Who Have Failed to Achieve or Maintain an IWG Response Following Hypomethylating Agent Therapy |
| Year | 2015 |
| Country | Belgium|Germany|United Kingdom |
| Company sponsor | Cell Medica Ltd |
| Other ID(s) | D-00272-CT2014002 |
| Cohort 1 | |||||||||
|
|||||||||